<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924169</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0371</org_study_id>
    <secondary_id>NCI-2014-01058</secondary_id>
    <nct_id>NCT01924169</nct_id>
  </id_info>
  <brief_title>Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if lenalidomide can increase the level&#xD;
      of immunoglobulins (parts of the blood that may help to improve the immune system's function)&#xD;
      and/or will improve the protective effect of the flu and pneumonia vaccines in patients with&#xD;
      CLL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will take lenalidomide by&#xD;
      mouth on Monday, Wednesday and Friday for 3 months.&#xD;
&#xD;
      In order to participate in this study you must register into and follow the requirements of&#xD;
      the Revlimid REMS™ program of Celgene Corporation. This program provides education and&#xD;
      counseling on the risks of fetal exposure, blood clots and reduced blood counts. You will be&#xD;
      required to receive counseling every 28 days during treatment with lenalidomide, follow the&#xD;
      pregnancy testing and birth control requirements of the program that are appropriate for you&#xD;
      and take telephone surveys regarding your compliance with the program.&#xD;
&#xD;
      Depending on how you respond to the drug, after 3 months, you will either:&#xD;
&#xD;
      °Take lenalidomide every Monday, Wednesday and Friday on a 3 months on/3 months off schedule.&#xD;
      You will then repeat this process for up to 2 years.&#xD;
&#xD;
      or&#xD;
&#xD;
      °Take lenalidomide every day for an extra 3 months. If you respond well, you will take&#xD;
      lenalidomide every day for 3 months, then for the next 3 months stop the drug. You will then&#xD;
      repeat this process for up to 2 years.&#xD;
&#xD;
      You should swallow the lenalidomide capsules whole with water. Do not open, crush, or break&#xD;
      the lenalidomide capsules. If you touch a broken lenalidomide capsule, wash the area of your&#xD;
      body with soap and water.&#xD;
&#xD;
      If you miss a dose of lenalidomide, and it has been less than 12 hours since your regular&#xD;
      dose time, take it as soon as you remember. If it has been more than 12 hours, just skip your&#xD;
      missed dose. Do not take 2 doses at the same time. If you take too much lenalidomide or&#xD;
      overdose, call your healthcare provider right away. If you vomit after any dose, do not take&#xD;
      another dose.&#xD;
&#xD;
      You will also receive a vaccine for the flu (Trivalent or Fluzone) 1 time a year. If you have&#xD;
      not received one in the last 5 years, you will receive a vaccine for pneumonia (Pneumovax)&#xD;
      between months 6 and 21. You will receive these vaccines as an injection under the skin.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Before the first dose of study drug:&#xD;
&#xD;
      °Blood (about 2 teaspoons) will be drawn to test cytokines (proteins that may affect the&#xD;
      immune system) and to test your immune system.&#xD;
&#xD;
      If you are able to become pregnant, 1 time a week for the first 4 weeks and then every 28&#xD;
      days while on treatment, you will have a blood (about 1 teaspoon) or urine pregnancy test.&#xD;
&#xD;
      While you are taking lenalidomide, blood (about 1 teaspoon) will be drawn for routine tests&#xD;
      every 2-4 weeks.&#xD;
&#xD;
      At 3 months (+/- 3 weeks):&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn for routine tests.&#xD;
&#xD;
      Before the flu vaccine, blood (about 1 teaspoons) will be drawn for antibody testing.&#xD;
      Antibodies are created by the immune system and may attack foreign cells or substances, such&#xD;
      as the study drug.&#xD;
&#xD;
      At 4 weeks (+/- 2 weeks) and 3 months (+/- 3 weeks) after the vaccine, blood (about 2&#xD;
      teaspoons) will be drawn for antibody testing, cytokine testing, and to test your immune&#xD;
      system.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will take the study drug for up to 2 years. You will no longer be able to take the study&#xD;
      drug if the disease gets worse, if intolerable side effects occur, or if you are unable to&#xD;
      follow study directions.&#xD;
&#xD;
      Your participation on the study will be over after the follow-up visits.&#xD;
&#xD;
      End of Study:&#xD;
&#xD;
      °Blood (about 2 teaspoons) will be drawn for antibody testing and cytokine testing.&#xD;
&#xD;
      This is an investigational study. Lenalidomide is FDA approved and commercially available for&#xD;
      the treatment of multiple myeloma, myelodysplastic syndrome and mantle cell lymphoma. The use&#xD;
      of this to help prevent infections by improving immunoglobulin levels and its use in&#xD;
      combination with the flu and pneumonia vaccine is investigational.&#xD;
&#xD;
      Up to 35 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date type="Actual">November 24, 2014</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">February 21, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With IgG Response</measure>
    <time_frame>6 months</time_frame>
    <description>IgG response defined as having improvement in IgG level by at least 25% at 6 months, compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Response</measure>
    <time_frame>4 weeks after flu vaccine administered</time_frame>
    <description>Study considered positive in regard to the secondary endpoints if seroconversion is observed in 60% or more of the subjects for at least one of the vaccinations given.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hematologic Disorder</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.&#xD;
If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>Administered as injection yearly, during the fall/winter season.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>TIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax Vaccine</intervention_name>
    <description>Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>Pneumonia vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic lymphocytic leukemia (CLL) patients with IgG less than 500 mg/dl with/without&#xD;
             symptoms who are either untreated or previously treated, regardless of response, at&#xD;
             least 6 months from prior therapy (including mAb)..&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance&#xD;
             status of 0-2.&#xD;
&#xD;
          3. Adequate renal functions as indicated by serum creatinine equal to or less than 2&#xD;
             mg/dl.&#xD;
&#xD;
          4. Adequate hepatic function indicated as total bilirubin equal to or less than 2 mg/dl&#xD;
             and alanine aminotransferase (ALT) equal to or less than two times the upper limit of&#xD;
             normal.&#xD;
&#xD;
          5. Disease free of prior malignancies for 3 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast. Patients with malignancies with indolent behavior such as prostate cancer&#xD;
             treated with radiation or surgery can be enrolled in the study as long as they have a&#xD;
             reasonable expectation to have been cured with the treatment modality received.&#xD;
&#xD;
          6. Females of childbearing potential (FCBP). A female of childbearing potential is a&#xD;
             sexually mature woman who: 1) has not undergone a hysterectomy or bilateral&#xD;
             oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive&#xD;
             months (i.e., has not had menses at any time in preceding 24 consecutive months)&gt;&#xD;
&#xD;
          7. FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least&#xD;
             50 mlU/mL within 10-14 days prior to and again within 24 hours of starting&#xD;
             lenalidomide from heterosexual intercourse or begin two acceptable methods of birth&#xD;
             control, one highly effective method and one additional effective method at the same&#xD;
             time, at least 28 days before she starts taking lenalidomide.&#xD;
&#xD;
          8. FCBP must also agree to ongoing pregnancy testing (weekly for the first four weeks and&#xD;
             then every 28 days while on therapy and at discontinuation of treatment).&#xD;
&#xD;
          9. Men must agree to use a latex condom during sexual contact with a FCBP even if they&#xD;
             have had a successful vasectomy. All patients must be counseled at a minimum of every&#xD;
             28 days about pregnancy precautions and risks of fetal exposure.&#xD;
&#xD;
         10. Patients must be 18 years of age or older.&#xD;
&#xD;
         11. All study participants must be registered into the mandatory Revlimid REMS® program,&#xD;
             and be willing and able to comply with the requirements of the REMS® program.&#xD;
&#xD;
         12. Females of reproductive potential must adhere to the scheduled pregnancy testing as&#xD;
             required in the Revlimid REMS® program. Able to take aspirin (81 or 325 mg) daily as&#xD;
             prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low&#xD;
             molecular weight heparin).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known sensitivity to lenalidomide or other thalidomide derivatives.&#xD;
&#xD;
          2. History of Guillain-Barre within 6 weeks of previous influenza vaccination.&#xD;
&#xD;
          3. Patient on steroid therapy.&#xD;
&#xD;
          4. Documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood) or&#xD;
             Richter's transformation.&#xD;
&#xD;
          5. Known positivity for HIV or active hepatitis B or C.&#xD;
&#xD;
          6. Pregnant or breast feeding females.&#xD;
&#xD;
          7. History of tuberculosis treated within the last five years or recent exposure to&#xD;
             tuberculosis.&#xD;
&#xD;
          8. Any serious medical condition, laboratory abnormality or psychiatric illness that&#xD;
             places the subject at unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
          9. Patients with a recent history of deep vein thrombosis (DVT) or pulmonary embolus&#xD;
             (PE), in six months prior to enrollment are not eligible for this study.&#xD;
&#xD;
         10. Subjects who have currently active hepatic or biliary disease (with the exception of&#xD;
             patients with Gilbert's syndrome).&#xD;
&#xD;
         11. Patients with severe allergic reaction (e.g., anaphylaxis) after previous dose of any&#xD;
             influenza vaccine or to a vaccine component, including egg protein.&#xD;
&#xD;
         12. Moderate or severe acute illness with or without fever.&#xD;
&#xD;
         13. Use of any other experimental drug or therapy within 28 days of baseline.&#xD;
&#xD;
         14. Concurrent use of other anti-cancer agents or treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Ferrajoli, MD,BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <results_first_submitted>February 9, 2018</results_first_submitted>
  <results_first_submitted_qc>February 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2018</results_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Disorder</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Hypogammaglobulinemia</keyword>
  <keyword>Impaired Response to Vaccinations</keyword>
  <keyword>Immunoglobulins</keyword>
  <keyword>Immune system's function</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Flu vaccine</keyword>
  <keyword>TIV</keyword>
  <keyword>Pneumonia vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 3, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01924169/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01924169/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>November 2014 through May 2016. All of the participants were recruited at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>Lenalidomide administered at the dose of 5 mg/day three times a day for three months. If IgG levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If Immunoglobulin G (IgG) levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.&#xD;
Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>Lenalidomide administered at the dose of 5 mg/day three times a day for three months. If IgG levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.&#xD;
Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="48" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With IgG Response</title>
        <description>IgG response defined as having improvement in IgG level by at least 25% at 6 months, compared to baseline.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Lenalidomide administered at the dose of 5 mg/day three times a day for three months. If IgG levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.&#xD;
Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With IgG Response</title>
          <description>IgG response defined as having improvement in IgG level by at least 25% at 6 months, compared to baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Response</title>
        <description>Study considered positive in regard to the secondary endpoints if seroconversion is observed in 60% or more of the subjects for at least one of the vaccinations given.</description>
        <time_frame>4 weeks after flu vaccine administered</time_frame>
        <population>The first three participants did not remain on study long enough to undergo immunizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Lenalidomide administered at the dose of 5 mg/day three times a day for three months. If IgG levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.&#xD;
Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Response</title>
          <description>Study considered positive in regard to the secondary endpoints if seroconversion is observed in 60% or more of the subjects for at least one of the vaccinations given.</description>
          <population>The first three participants did not remain on study long enough to undergo immunizations.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants will be assessed for adverse events from the first dose of study medication to the completion of study treatment, up to 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>Lenalidomide administered at the dose of 5 mg/day three times a day for three months. If IgG levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.&#xD;
Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alessandra Ferrajoli, MD/Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

